Results

1–10 of 36 results for anti-VEGF therapy

Progression of Geographic Atrophy in Patients Receiving Both Anti-VEGF and Pegcetacoplan Injections
Sean David Adrean, MD, FAAO, FASRS
Annual Meeting Talks
2025
Safety of Continuing Anti-VEGF Therapy Around the Time of Nonophthalmic Incisional Surgery: A Multisite Matched Cohort Study
Odette M. Houghton, MD
Updates from the Field
2026
Daily Imaging With Home Optical Coherence Tomography Among Treatment-Naive Neovascular Age-Related Macular Degeneration Participants
Kevin J. Blinder, MD, FASRS
Annual Meeting Talks
2023
Safety and Tolerability of Suprachoroidal Injection of CLS-AX in Neovascular AMD Patients With Persistent Activity After Anti-VEGF Therapy
Rahul N. Khurana, MD, FASRS
Annual Meeting Talks
2023
Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Annual Meeting Talks
2024
Baseline Characteristics Associated With Catastrophic Vision Loss Due to Subretinal Hemorrhage in Patients Undergoing Treatment for Neovascular Macular Degeneration
Eric W Schneider, MD
Annual Meeting Talks
2024
Subretinal Delivery of Investigational ABBV-RGX-314 for Neovascular Age-Related Macular Degeneration: A Phase II Pharmacodynamic Study
Edward H. Wood, MD, FASRS
Annual Meeting Talks
2024
Impact of COVID-19 and Delay on Macular Edema After Retinal Vein Occlusion (MEfRVO) Comparing Ozurdex vs Anti-VEGF Therapy
John J. Huang, MD
Annual Meeting Talks
2022
Anti-VEGF Therapy to Prevent Macular Fibrosis in Coats Disease
On Demand Cases, Courses, and Papers
2022
Impact of Intravitreal Anti-VEGF Therapy for Severe Non-Proliferative Diabetic Retinopathy (NPDR): Analyses Through a Monte-Carlo Simulation Model
Andrew A. Moshfeghi, MD, MBA, FASRS
On Demand Cases, Courses, and Papers
2021